Kronos Bio LLC

Kronos Bio LLC Current Assets

Delisted

The Current Assets of Kronos Bio LLC (KRON) as of Nov 2, 2026 is 115.23 M USD. In the previous year, Current Assets was 178.78 M USD — a change of -35.55% (lower).

Current Assets

115.23 MUSD

YoY

-35.55%

Last updated:

Current Assets of Kronos Bio LLC is 2024 115.23 M USD. Current Assets of Kronos Bio LLC was 2023 178.78 M USD. It decreases by -35.55% lower compared to the previous year.

The Kronos Bio LLC Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
10.54 M USD
Jan 1, 2019
93.31 M USD
Jan 1, 2020
418.94 M USD
Jan 1, 2021
347.54 M USD
Jan 1, 2022
243.75 M USD
Jan 1, 2023
178.78 M USD
Jan 1, 2024
115.23 M USD
The Kronos Bio LLC Current Assets history
YEARCurrent AssetsYoY
115.23 MUSD-35.55%
178.78 MUSD-26.65%
243.75 MUSD-29.86%
347.54 MUSD-17.04%
418.94 MUSD+349.00%
93.31 MUSD+785.16%
10.54 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kronos Bio LLC Stock analysis

What does Kronos Bio LLC do? Kronos Bio Inc is a biotech company founded in 2017 by an experienced team, specialized in developing new therapeutics for cancer treatment. The company is based in Cambridge, Massachusetts and collaborates closely with leading scientific institutions. Kronos Bio Inc's business model focuses on identifying and researching new targets to develop drugs for the treatment of cancer and other diseases. The company utilizes artificial intelligence and machine learning to identify molecular mechanisms, enabling better prediction of the effectiveness of new drugs. Kronos Bio Inc is divided into different divisions, each focusing on specific therapeutic approaches. The "Transcription Regulation" division explores the control of gene expression in tumor cells and seeks potential points of intervention. The "Epigenetics" division, on the other hand, investigates how cells modify their DNA and the role this plays in the development of cancer. Another division focuses on blocking specific enzyme activities that are considered essential factors for the growth of tumor cells. Currently, Kronos Bio Inc does not offer concrete products as it is still in the development phase. However, the company has already established a number of collaborations with other companies and scientific institutions to research and further develop new drug candidates. One of the most significant partnerships is with the pharmaceutical company Gilead Sciences, which has the option to license selected drug candidates from Kronos Bio Inc as part of the collaboration. Overall, Kronos Bio has quickly made a name for itself in the biotech industry with its innovative approach and ambitious plans to develop new drugs against cancer. The company has raised several million dollars in capital and has prominent investors such as Omega Funds and Vida Ventures on board. The goal of Kronos Bio is to develop new therapies that allow for improved survival rates and a higher quality of life for cancer patients. Kronos Bio LLC is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kronos Bio LLC stock

Current Assets of Kronos Bio LLC is 115.23 M USD in 2024.

Current Assets of Kronos Bio LLC changed from 178.78 M USD to 115.23 M USD, representing a -35.55% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Kronos Bio LLC since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Kronos Bio LLC historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Kronos Bio LLC

All Key Metrics — Kronos Bio LLC